Two Pacemaker Placements After AV Node Ablation in Atrial Fibrillation
Compares two pacemaker lead positions after AV node ablation in atrial fibrillation.
Plain-language title generated from the registry record
Registry title: AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function
Key facts
- Where
- Hagen and Wiesbaden, GermanySee the 2 sites
Where in Germany
- Evangelisches Krankenhaus Hagen-HaspeHagen, GermanyNot yet recruiting
- St. Josefs-Hospital Wiesbaden GmbHWiesbaden, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- St. Josefs-Hospital Wiesbaden GmbH
- Trial code
- NCT07428967
- Record updated
- 24 February 2026
- Original description
AVA CONDUCT is a prospective, multicenter, randomized study with single blinding, comparing left bundle branch area (LBBA) pacing with right ventricular (RV) pacing following AV node ablation in terms of clinical, functional, and electrophysiological outcomes.Read full original descriptionShow less
AtrioVentricular Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function - a Randomized Controlled Trial
AVA CONDUCT is a prospective, multicenter, randomized study with single blinding, comparing left bundle branch area (LBBA) pacing with right ventricular (RV) pacing following AV node ablation in terms of clinical, functional, and electrophysiological outcomes.
The primary hypothesis is that pacing-induced cardiomyopathy, defined as a decrease in LVEF by 10% or more from baseline to an absolute value below 50%, occurs significantly more frequently in patients receiving RV pacing compared with LBBA pacing. Secondarily, LBBA pacing is expected to maintain comparable procedural safety while providing better cardiac function, resulting in improved quality of life and functional capacity compared with conventional RV pacing.
Inclusion: History of symptomatic AF (EHRA IIb - IV) despite guideline-indicated medical or interventional therapy; Preserved LVEF (≥ 50%, assessed by echocardiography, Simpson's biplane method); AV node ablation scheduled independently of possible study participation; Age ≥ 18 years; Consent capacity.
Exclusion: Surgical coronary revascularization (within the last 30 days) or current triple therapy after stent PCI; High grade (III°) left cardiac valvular disease; Impaired LVEF (< 50%); Pre-implanted pacemaker; Contraindication for pacemaker implantation or AV node ablation (see chapter 5.3 for details); Body-mass-index > 40 kg/m2; Pregnancy; Inability to give written informed consent; Life expectancy < 12 months.